                </a></li></ul></div><p><strong>Figure 1. </strong></p><a id="article1.body1.sec2.sec1.fig1.caption1.p1" name="article1.body1.sec2.sec1.fig1.caption1.p1"></a><p>Tumor growth and metastasis are inhibited in PPARα knockout (KO) mice. PPARα wild type (WT) and PPARα KO mice were injected subcutaneously or intravenously with various tumor cell lines; (n) = number of mice/group. (A–C) The growth of engineered PPARα(+/+) MEF/RS and PPARα(−/−) MEF/RS tumors in PPARα WT and KO mice. (A) PPARα(+/+)MEF/RS tumor growth in PPARα WT (♦ gray) and KO (▪ brown) mice. (B) The growth curves of PPARα(−/−)MEF/RS in PPARα WT (♦ gray) and KO (▪ brown) mice.(C) Columns summarize the inhibitory effect of PPARα (−/−) tumor and host cells at day 30 post implantation (average±standard error of the mean). (D–F) The growth of different murine tumors in different mouse strains. (D) The growth of B16-BL6 melanoma was compared in WTS1 (♦ gray), WTS1/S4 (▴gray), KOS4 (▪ brown) and KO S1/S4 (♦ pink) strains. WT S1/S4, PPARα WT second generation littermates from PPARα WT 129/S1 and KO 129/S4; KO S1/S4, PPARα KO second generation littermates from PPARα KO 129/S4. (E) Lewis lung carcinoma growth in PPARα WT (♦ gray), PPARα KO (▪ brown) and C57BL/6 (▴ blue) mice. (F) B16-F10/GFP tumor growth in PPARα WT, PPARα KO and C57BL/6 mice, blue insets demonstrate representative B16-F10/GFP tumors in PPARα WT and KO mice on day 30 post implantation. Scale bar, 1 cm. (G) B16-BL6 melanoma was implanted in mice of indicated genetic backgrounds. Representative B16-BL6 tumors in PPARα WT (♦ gray) and PPARα KO (▪ brown) mice on day 30 post implantation are shown (blue insets). Scale bar, 1 cm. (H–I) Metastasis in PPARα WT and KO mice. H: Metastatic areas of B16-F10/GFP and PPARα(−/−)MEF/RS tumor cells at day 21 post-injection in lung and liver of PPARα WT (♦ gray) and KO mice (▪ brown). I: Number of liver metastases in PPARα WT (▪ gray) and KO (▪ brown) mice injected with B16-F10/GFP tumor cells (average±standard deviation).</p>
<span>THISISTHEEND
